Dorsey Wright & Associates Reduces Holdings in GALAPAGOS NV/S (GLPG)

Dorsey Wright & Associates lessened its stake in shares of GALAPAGOS NV/S (NASDAQ:GLPG) by 33.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 65,744 shares of the biotechnology company’s stock after selling 32,800 shares during the period. GALAPAGOS NV/S accounts for approximately 1.3% of Dorsey Wright & Associates’ holdings, making the stock its 17th biggest position. Dorsey Wright & Associates owned 0.13% of GALAPAGOS NV/S worth $7,391,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Castleark Management LLC boosted its holdings in shares of GALAPAGOS NV/S by 47.2% during the 2nd quarter. Castleark Management LLC now owns 9,870 shares of the biotechnology company’s stock valued at $910,000 after purchasing an additional 3,166 shares during the last quarter. Putnam Investments LLC boosted its holdings in shares of GALAPAGOS NV/S by 8.5% during the 2nd quarter. Putnam Investments LLC now owns 22,682 shares of the biotechnology company’s stock valued at $2,091,000 after purchasing an additional 1,770 shares during the last quarter. Aquilo Capital Management LLC bought a new position in shares of GALAPAGOS NV/S during the 2nd quarter valued at about $6,088,000. Macquarie Group Ltd. boosted its holdings in shares of GALAPAGOS NV/S by 13.5% during the 2nd quarter. Macquarie Group Ltd. now owns 9,865 shares of the biotechnology company’s stock valued at $909,000 after purchasing an additional 1,170 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of GALAPAGOS NV/S by 11.7% during the 2nd quarter. Bank of America Corp DE now owns 9,758 shares of the biotechnology company’s stock valued at $899,000 after purchasing an additional 1,025 shares during the last quarter. 14.64% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:GLPG traded up $1.65 during trading on Friday, reaching $99.59. The company’s stock had a trading volume of 73,700 shares, compared to its average volume of 111,014. GALAPAGOS NV/S has a 12 month low of $84.13 and a 12 month high of $122.28. The company has a market cap of $5.76 billion, a price-to-earnings ratio of -37.72 and a beta of 2.00.

GALAPAGOS NV/S (NASDAQ:GLPG) last announced its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.50) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.91) by $0.41. GALAPAGOS NV/S had a negative net margin of 70.80% and a negative return on equity of 13.26%. The firm had revenue of $59.27 million during the quarter, compared to the consensus estimate of $50.58 million. As a group, equities research analysts predict that GALAPAGOS NV/S will post -3.12 earnings per share for the current fiscal year.

Several research firms have commented on GLPG. Stifel Nicolaus increased their price objective on shares of GALAPAGOS NV/S from $109.00 to $111.00 and gave the company a “buy” rating in a report on Wednesday, September 12th. JPMorgan Chase & Co. began coverage on shares of GALAPAGOS NV/S in a report on Wednesday, September 12th. They set an “overweight” rating and a $140.00 price objective for the company. BidaskClub raised shares of GALAPAGOS NV/S from a “sell” rating to a “hold” rating in a report on Tuesday, September 18th. Goldman Sachs Group downgraded shares of GALAPAGOS NV/S from a “buy” rating to a “neutral” rating in a report on Thursday, August 9th. Finally, Zacks Investment Research downgraded shares of GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a report on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $114.57.

GALAPAGOS NV/S Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Featured Article: Dividend

Institutional Ownership by Quarter for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply